3. DHA‐P versus AS+MQ: Additional secondary outcomes data.
| Outcome | Study ID | Measure | DHA‐P | AS+MQ | P value | Comment |
| Gametocyte carriage | Grande 2007 PER | Person gametocytemia weeks per 1000 person weeks | 32.5 | 24.9 | 0.31 | |
| Mayxay 2006 LAO | Proportion with gametocytes at any timepoint after treatment (on or after day 7) | 9/110 | 3/110 | 0.07 | ||
| Person gametocytemia weeks per 1000 person weeks | ‐ | ‐ | > 0.05 | Mean across all groups was 0.10 (95% CI 0.03 to 0.20). No difference between groups (published data). | ||
| Smithuis 2006 MMR | Gametocyte incidence at day 7 | 18/188 | 5/218 | 0.01 | ||
| Gametocyte incidence at day 14 | 3/168 | 1/212 | 0.12 | |||
| Person gametocytemia weeks per 1000 person weeks | ‐ | ‐ | 0.03 | Gametocyte carriage in DHA‐P group was higher than in AS+MQ group (published data). Figures not given. | ||
| Smithuis 2010 MMR | Person gametocytemia weeks per 1000 person weeks | 112.8 | 29.5 | Not stated | Data presented are for fixed‐dose AS+MQ combination. | |
| Valecha 2010 AS | Person gametocytemia weeks per 1000 person weeks | 20.2 (130/6420) |
7.4 (23/3108) |
0.01 | Published data in paper presented as "person gametocytemia weeks per 100 person weeks". | |
| Anaemia | Ashley 2004b THA | Median decrease in HCT by day 7 | 6.3% | 9.4% | 0.21 | "Mean decrease in HCT up to day 7 then recovery in all groups". |
| Ashley 2005 THA | Absolute changes in HCT | ‐ | ‐ | ‐ | "Mean decrease in HCT up to day 7 then recovery in all groups". | |
| Janssens 2007 KHM | Mean HCT at day 63 | 40.0 % (3.7) | 40.2% (3.8) | Not stated | "Patients in both treatment groups showed similar haematological recovery during the 63‐day follow‐up period". | |
| Mayxay 2006 LAO | Mean HCT days 7 to 42 | Not stated | Not stated | > 0.05 | "the mean hematocrit after treatment did not significantly differ between groups". | |
| Smithuis 2006 MMR | Mean haemoglobin at day 28 | 10.4 g/dL | 10.5 g/dL | 0.65 | Data presented are for supervised treatment groups. | |
| Proportion anaemic (Hb < 10 g/dL) on day 28 | 56/152 | 59/156 | 0.85 | Data presented are for supervised treatment groups. | ||
| Smithuis 2010 MMR | Mean increase in haemoglobin | Not stated | Not stated | > 0.05 | "The mean increase of haemoglobin was similar among the treatment groups". | |
| Valecha 2010 AS | Mean increase in Hb from day 0 to day 63 in g/dL | 1.28 ± 2.22 | 1.42 ± 2.12 | 0.30 |
Hb ‐ Haemoglobin HCT ‐ Haematocrit